Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 1/2016

01-01-2016 | Gynecologic Endocrinology and Reproductive Medicine

Effects of GnRHa on early embryonic development in mice receiving cyclophosphamide

Authors: Mehmet Kanter, Melike Sapmaz-Metin, Bilkay Serez

Published in: Archives of Gynecology and Obstetrics | Issue 1/2016

Login to get access

Abstract

Purpose

There is a controversy whether GnRH agonist can reduce the deleterious effects of chemotherapy to prevent ovarian failure. We aimed to examine the possible protective effects of a gonadotrophin-releasing hormone agonist (GnRHa) on the fertilization rate and sequential embryonic development in mouse oocytes exposed to Cy.

Methods

Mice were assigned to three groups of six animals each. A single dose of 75 mg/kg Cy was given intraperitoneally to the Cy mice group. The subcutaneous GnRHa injection was initiated 1 week before and continued for 1 week after the Cy injection in the GnRHa + Cy group. The animals given cyclophosphamide mated 1 week after the Cy injection. At the end of the injection period, the animals underwent a superovulation regime with pregnant mare serum gonadotrophin and human chorionic gonadotrophin and were mated. Early embryos were collected at 48 h after mating. The control group received only the superovulation regime and then mated.

Results

Cyclophosphamide caused a significant decrease in the fertilization rate (p < 0.001), whereas the GnRHa improved the rate when compared to control group. The GnRHa induced a marked increase in the rate for 2-cell embryos compared with the Cy group (p = 0.003). In both Cy-injected groups, the rates for the 4-cell embryos were lower than those of the control animals (p < 0.001). However, this rate was higher in the GnRHa + Cy group than in the only Cy group. Morphologically abnormal embryos showed such characteristics as condensed cytoplasm, milky cytoplasm, fragmentation, and an empty zona pellucida.

Conclusion

These results demonstrated that the GnRHa preserved the oocyte capability to develop into an embryo against ovarian toxic chemotherapy. Thus, we suggest that GnRHa cotreatment could increase the number and quality of early embryos in mice.
Literature
1.
go back to reference Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L (2011) Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 33:369–383PubMedCrossRef Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L (2011) Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 33:369–383PubMedCrossRef
2.
go back to reference Blumenfeld Z, Avivi I, Ritter M, Rowe JM (1999) Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Invest 6:229–239CrossRef Blumenfeld Z, Avivi I, Ritter M, Rowe JM (1999) Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Invest 6:229–239CrossRef
3.
go back to reference Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O, Fehm T, Rezai M, Mehta K, Loibl S (2011) Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 29:2334–2341. doi:10.1200/JCO.2010.32.5704 PubMedCrossRef Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, Fischer D, Sommer HL, Conrad B, Ortmann O, Fehm T, Rezai M, Mehta K, Loibl S (2011) Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 29:2334–2341. doi:10.​1200/​JCO.​2010.​32.​5704 PubMedCrossRef
4.
go back to reference Ataya KM, Valeriote FA, Ramahi-Ataya AJ (1989) Effect of cyclophosphamide on the immature rat ovary. Cancer Res 49:1660–1664PubMed Ataya KM, Valeriote FA, Ramahi-Ataya AJ (1989) Effect of cyclophosphamide on the immature rat ovary. Cancer Res 49:1660–1664PubMed
5.
go back to reference Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB (1995) Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res 330:115–181 (Review) PubMedCrossRef Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB (1995) Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res 330:115–181 (Review) PubMedCrossRef
6.
go back to reference Meirow D, Lewis H, Nugent D, Epstein M (1999) Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 14:1903–1907PubMedCrossRef Meirow D, Lewis H, Nugent D, Epstein M (1999) Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 14:1903–1907PubMedCrossRef
7.
go back to reference Plowchalk DR, Mattison DR (1992) Reproductive toxicity of cyclophosphamide in the C5BL/6N mouse: 1. Effects of ovarian structure and function. Reprod Toxicol 6:411–421PubMedCrossRef Plowchalk DR, Mattison DR (1992) Reproductive toxicity of cyclophosphamide in the C5BL/6N mouse: 1. Effects of ovarian structure and function. Reprod Toxicol 6:411–421PubMedCrossRef
8.
go back to reference Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM (1993) Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin’s disease. Hum Reprod 8:2080–2087PubMed Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM (1993) Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin’s disease. Hum Reprod 8:2080–2087PubMed
9.
go back to reference Nicosia SV, Matus-Ridley M, Meadows AT (1985) Gonadal effects of cancer theraphy in girls. Cancer 55:2364–2372PubMedCrossRef Nicosia SV, Matus-Ridley M, Meadows AT (1985) Gonadal effects of cancer theraphy in girls. Cancer 55:2364–2372PubMedCrossRef
10.
go back to reference Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K, American Society of Clinical Oncology (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2500–2510PubMedCrossRef Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K, American Society of Clinical Oncology (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2500–2510PubMedCrossRef
11.
go back to reference Shalev E, Leung PC (2003) Gonadotropin-releasing hormone and reproductive medicine. J Obstet Gynaecol Can 25:98–113PubMed Shalev E, Leung PC (2003) Gonadotropin-releasing hormone and reproductive medicine. J Obstet Gynaecol Can 25:98–113PubMed
12.
go back to reference Imai A, Furui T (2007) Chemotherapy-induced female infertility and protective action of gonadotropin-releasing hormone analogues. J Obstet Gynaecol 27:202–204CrossRef Imai A, Furui T (2007) Chemotherapy-induced female infertility and protective action of gonadotropin-releasing hormone analogues. J Obstet Gynaecol 27:202–204CrossRef
13.
go back to reference Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ (2005) Use of a Gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 52:2761–2767PubMedCrossRef Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ (2005) Use of a Gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 52:2761–2767PubMedCrossRef
14.
go back to reference Blumenfeld Z, Dann E, Avivi I et al (2002) Fertility after treatment for Hodgkin’s disease. Ann Oncol 13:138–147PubMedCrossRef Blumenfeld Z, Dann E, Avivi I et al (2002) Fertility after treatment for Hodgkin’s disease. Ann Oncol 13:138–147PubMedCrossRef
15.
go back to reference Kishk EA, Mohammed Ali MH (2013) Effect of a gonadotropin-releasing hormone analogue on cyclophosphamide-induced ovarian toxicity in adult mice. Arch Gynecol Obstet 287:1023–1029PubMedCrossRef Kishk EA, Mohammed Ali MH (2013) Effect of a gonadotropin-releasing hormone analogue on cyclophosphamide-induced ovarian toxicity in adult mice. Arch Gynecol Obstet 287:1023–1029PubMedCrossRef
16.
go back to reference Yuce MA, Kaplan PB, Gucer F, Doganay L, Altaner S, Canda T et al (2004) Prevention of Cyclophosphamide-induced ovarian damage by concomitant administration of GnRHa in mice: a dose-dependent relationship? Eur J Gynaecol Oncol 25:628–631PubMed Yuce MA, Kaplan PB, Gucer F, Doganay L, Altaner S, Canda T et al (2004) Prevention of Cyclophosphamide-induced ovarian damage by concomitant administration of GnRHa in mice: a dose-dependent relationship? Eur J Gynaecol Oncol 25:628–631PubMed
17.
go back to reference Danforth DR, Arbogast LK, Friedman CI (2005) Acute depletion of murine primordial follicle reserve by Gonadotropin-releasing hormone antagonists. Fertil Steril 83:1333–1338PubMedCrossRef Danforth DR, Arbogast LK, Friedman CI (2005) Acute depletion of murine primordial follicle reserve by Gonadotropin-releasing hormone antagonists. Fertil Steril 83:1333–1338PubMedCrossRef
18.
go back to reference Ataya K, Ramahi-Ataya A (1993) Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reprod Toxicol 7:229–235PubMedCrossRef Ataya K, Ramahi-Ataya A (1993) Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reprod Toxicol 7:229–235PubMedCrossRef
19.
go back to reference Letterie GS (2004) Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure. Hum Reprod 19:831–837PubMedCrossRef Letterie GS (2004) Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure. Hum Reprod 19:831–837PubMedCrossRef
20.
go back to reference Parlakgumus HA, Kilicdag EB, Bolat FA, Haydardedeoglu B, Parlakgumus A (2014) GNRH agonists and antagonists in rescue for cyclophosphamide-induced ovarian damage: friend or foe? Arch Gynecol Obstet. [Epub ahead of print] Parlakgumus HA, Kilicdag EB, Bolat FA, Haydardedeoglu B, Parlakgumus A (2014) GNRH agonists and antagonists in rescue for cyclophosphamide-induced ovarian damage: friend or foe? Arch Gynecol Obstet. [Epub ahead of print]
21.
go back to reference Maltaris T, Koelbl H, Seufert R, Kiesewetter F, Beckmann MW, Mueller A et al (2006) Gonadal damage and options for fertility preservation in female and male cancer survivors. Asian J Androl 8:515–533PubMedCrossRef Maltaris T, Koelbl H, Seufert R, Kiesewetter F, Beckmann MW, Mueller A et al (2006) Gonadal damage and options for fertility preservation in female and male cancer survivors. Asian J Androl 8:515–533PubMedCrossRef
22.
go back to reference Pydyn EF, Ataya KM (1991) Effect of cyclophosphamide on mouse oocyte in vitro fertilisation and cleavage: recovery. Reprod Toxicol 5:73–78PubMedCrossRef Pydyn EF, Ataya KM (1991) Effect of cyclophosphamide on mouse oocyte in vitro fertilisation and cleavage: recovery. Reprod Toxicol 5:73–78PubMedCrossRef
23.
go back to reference Zhu BK, Walker SK, Maddocks S (2004) Optimisation of in vitro culture conditions in B6CBF1 mouse embryos. Reprod Nutr Dev 44:219–231PubMedCrossRef Zhu BK, Walker SK, Maddocks S (2004) Optimisation of in vitro culture conditions in B6CBF1 mouse embryos. Reprod Nutr Dev 44:219–231PubMedCrossRef
24.
go back to reference Ataya K, Pydyn E, Ramahi-Ataya A, Orton CG (1995) Is radiation-induced ovarian failure in rhesus monkeys preventable by luteinizing hormone-releasing hormone agonist?: preliminary observations. J Clin Endocrinol Metab 80:790–795PubMed Ataya K, Pydyn E, Ramahi-Ataya A, Orton CG (1995) Is radiation-induced ovarian failure in rhesus monkeys preventable by luteinizing hormone-releasing hormone agonist?: preliminary observations. J Clin Endocrinol Metab 80:790–795PubMed
25.
go back to reference Pereyra Pacheco B, Méndez Ribas JM, Milone G, Fernández I, Kvicala R, Mila T et al (2001) Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 81:391–397PubMedCrossRef Pereyra Pacheco B, Méndez Ribas JM, Milone G, Fernández I, Kvicala R, Mila T et al (2001) Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 81:391–397PubMedCrossRef
26.
go back to reference Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N (1996) Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 11:1620–1626PubMedCrossRef Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N (1996) Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 11:1620–1626PubMedCrossRef
27.
go back to reference Beck-Fruchter R, Weiss A, Shalev E (2008) GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 14:553–561PubMedCrossRef Beck-Fruchter R, Weiss A, Shalev E (2008) GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 14:553–561PubMedCrossRef
28.
go back to reference Barekati Z, Gourabi H, Valojerdi MR, Yazdi PE (2008) Previous maternal chemotherapy by cyclophosphamide (Cp) causes numerical chromosome abnormalities in preimplantation mouse embryos. Reprod Toxicol 26:278–281PubMedCrossRef Barekati Z, Gourabi H, Valojerdi MR, Yazdi PE (2008) Previous maternal chemotherapy by cyclophosphamide (Cp) causes numerical chromosome abnormalities in preimplantation mouse embryos. Reprod Toxicol 26:278–281PubMedCrossRef
29.
go back to reference Banka CL, Erickson GF (1985) Gonadotropin-releasing hormone induces classical meiotic maturation in subpopulations of atretic preantral follicles. Endocrinology 117:1500–1507PubMedCrossRef Banka CL, Erickson GF (1985) Gonadotropin-releasing hormone induces classical meiotic maturation in subpopulations of atretic preantral follicles. Endocrinology 117:1500–1507PubMedCrossRef
30.
go back to reference Blumenfeld Z (2008) GnRH-agonists in fertility preservation. Curr Opin Endocrinol Diabetes Obes 15:523–528PubMedCrossRef Blumenfeld Z (2008) GnRH-agonists in fertility preservation. Curr Opin Endocrinol Diabetes Obes 15:523–528PubMedCrossRef
31.
go back to reference Meirow D, Epstein M, Lewis H, Nugent D, Gosden RG (2001) Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod 16:632–637PubMedCrossRef Meirow D, Epstein M, Lewis H, Nugent D, Gosden RG (2001) Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod 16:632–637PubMedCrossRef
Metadata
Title
Effects of GnRHa on early embryonic development in mice receiving cyclophosphamide
Authors
Mehmet Kanter
Melike Sapmaz-Metin
Bilkay Serez
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 1/2016
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-015-3831-x

Other articles of this Issue 1/2016

Archives of Gynecology and Obstetrics 1/2016 Go to the issue